anti-CD19 CAR-T cells for scleroderma, systemic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Apr 2026: Trial registered, NCT07544225

The trials

NCT07544225: Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases

State
Not started
Phase
Phase 1
People
6 planned
Started
1 Dec 2026
Primary completion
1 Feb 2029
Arms
Treatment
Results
None posted
  1. 22 Apr 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.